SecBot SecBot
6-K ·Filed May 6, 2026

CMMB

Chemomab Therapeutics Ltd.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001178913-26-002423
Notable filing: 6-K
Actionable Insight • Neutral

Routine annual meeting results, no immediate trading catalyst. Monitor for any subsequent capital raise or share issuance under the newly increased authorized capital.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.74
T+0 close · May 6, 2026 · via day close
Latest settled
−6.90%
T+60 · $1.62
Vs SPY
−10.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $1.74entry
  2. T+1 · 6mo ago +1.72%α +0.89% · $1.77
  3. T+5 · 6mo ago 0.00%α −1.50% · $1.74
  4. T+20 · 6mo ago −1.15%α −4.29% · $1.72
  5. T+60 · 4mo ago −6.90%α −10.73% · $1.62

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab Therapeutics filed a 6-K reporting results of its annual general meeting held on May 5, 2026. Shareholders approved the re-election of directors, compensation policy, an increase in authorized share capital, and reappointment of auditors. This is routine governance with no material financial impact.

Key Facts

  • Re-elected Neil Cohen and Dr. Claude Nicaise as Class II directors
  • Approved compensation policy for office holders and directors
  • Approved increase in authorized share capital and amended articles accordingly
  • Re-appointed Somekh Chaikin (KPMG) as independent auditor for FY2026

Financial Impact

No material financial impact; authorized share increase allows future capital raises but no immediate dilution

dilution

Risk Factors

  • Potential future dilution from increased authorized capital if shares are issued

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-002423
Document: 0001178913-26-002423-index-headers.html0001178913-26-002423
Document: 0001178913-26-002423-index.html0001178913-26-002423
Document: 0001178913-26-002423.txt0001178913-26-002423

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026